论文部分内容阅读
采用细胞培养生物学方法和放射受体分析法检测甲状腺疾病患者血清甲状腺刺激抗体（ＴＳＡｂ）和促甲状腺激素结合抑制免疫球蛋白（ＴＢＩＩ）。发现Ｇｒａｖｅｓ病未治组ＴＳＡｂ和ＴＢＩＩ活性与阳性率明显高于Ｇｒａｖｅｓ病缓解组和桥本甲状腺炎（ＨＴ）组，后两组ＴｓＡｂ和ＴＢＩＩ活性与阳性率高于甲状腺腺瘤组和正常对照组。Ｇｒａｖｅｓ病未治组、缓解组和ＨＴ组其ＴＳＡｂ和ＴＢＩＩ的检出率分别为９１．７％和７９．２％、４８．０％和４４．０％及２３．１％和６１．５％。甲状腺腺瘤组和对照组ＴＳＡｂ和ＴＢＩＩ均为阴性，其活性亦无统计学差异。血清ＴＳＡｂ与ＴＢＩＩ活性以及ＴＳＡｂ、ＴＢＩＩ活性与Ｔ＿３、Ｔ＿４、ＦＴ＿３和ＦＴ＿４浓度之间均无显著相关性。提示ＴＳＨ受体抗体具有异质性，联合检测这两种抗体对了解自身免疫性甲状腺疾病（ＡＩＴＤ）的发病机理，合理诊治甲状腺疾病具有重要的临床价值。
Serum thyroid stimulating antibody (TSAb) and thyrotropin-binding inhibitory immunoglobulin (TBII) were measured in patients with thyroid disease using cell culture biology and radioimmunoassay. Found that the activity and positive rate of TSAb and TBII in the untreated Graves disease group were significantly higher than those in the Graves disease remission group and the Hashimoto’s thyroiditis group (HT). The positive rates of TsAb and TBII in the latter two groups were higher than those in the thyroid adenoma group and the normal control group . The detection rates of TSAb and TBII in the untreated group, remission group and HT group were 91.7% and 79.2%, 48.0% and 44.0% and 23.1% and 61.5% respectively in Graves disease group, . Thyroid adenoma group and control group TSAb and TBII were negative, no significant difference in its activity. Serum TSAb and TBII activity and TSAb, TBII activity and T_3, T_4, FT_3 and FT_4 concentrations were not significantly correlated. Suggesting that the TSH receptor antibodies have heterogeneity. Combined detection of these two antibodies has important clinical value in understanding the pathogenesis of autoimmune thyroid disease (AITD) and in the diagnosis and treatment of thyroid diseases.